Carotid intima media thickness is related positively to plasma pre β-high density lipoproteins in non-diabetic subjects

Clinica Chimica Acta

Volumn 413, Issue 3-4, 2012, Pages 473-477

  de Vries, Rindert ^a   Perton, Frank G ^a   van Tol, Arie ^a,b   Dullaart, Robin P F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

High density lipoproteins; Intima media thickness; Pre HDL

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PRE BETA HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGE; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSSED IMMUNOELECTROPHORESIS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; DIABETES MELLITUS; ELECTROPHORESIS; FEMALE; HIGH-DENSITY LIPOPROTEINS, PRE-BETA; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84355161451     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.11.001     Document Type: Article

References (45)

1. Lewington S., Whitlock G., et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007, 370:1829-1839. Prospective Studies Collaboration.
2. Di Angelantonio E., Sarwar N., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000. Emerging Risk Factors Collaboration.
3. Eisenberg S. High density lipoprotein metabolism. J Lipid Res 1984, 25:1017-1058.
4. Rosenson R.S., Brewer H.B., Chapman M.J., et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011, 57:392-410.
5. Singh I.M., Shishehbor M.H., Ansell B.J. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 2007, 298:786-798.
6. Borggreve S.E., de Vries R., Dullaart R.P.F. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003, 33:1051-1069.
7. Asztalos B.F., Roheim P.S., Milani R.L., et al. Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2000, 20:2670-2676.
8. Asztalos B.F., Cupples L.A., Demissie S., et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2004, 24:2181-2187.
9. Asztalos B.F., Collins D., Cupples L.A., et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 2005, 25:2185-2191.
10. Castro G.R., Fielding C.J. Early incorporation of cell-derived cholesterol into pre- beta-migrating high-density lipoprotein. Biochemistry 1988, 27:25-29.
11. Rye K.A., Clay M.A., Barter P.J. Remodelling of high density lipoproteins by plasma factors. Atherosclerosis 1999, 145:227-238.
12. Rye K.A., Barter P.J. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2004, 24:421-428.
13. Favari E., Lee M., Calabresi L., et al. Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1- but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein. J Biol Chem 2004, 279:9930-9936.
14. de Vries R., Groen A.K., Perton F.G., et al. Increased cholesterol efflux from cultured fibroblasts to plasma from hypertriglyceridemic type 2 diabetic patients: roles of pre beta-HDL, phospholipid transfer protein and cholesterol esterification. Atherosclerosis 2008, 196:733-741.
15. Watanabe H., Soderlund S., Soro-Paavonen A., et al. Decreased high-density lipoprotein (HDL) particle size, prebeta-, and large HDL subspecies concentration in Finnish low-HDL families: relationship with intima-media thickness. Arterioscler Thromb Vasc Biol 2006, 26:897-902.
16. Hattori H., Kujiraoka T., Egashira T., et al. Association of coronary heart disease with pre-beta-HDL concentrations in Japanese men. Clin Chem 2004, 50:589-595.
17. Miida T., Nakamura Y., Inano K., et al. Pre beta 1-high-density lipoprotein increases in coronary artery disease. Clin Chem 1996, 42:1992-1995.
18. Suzuki M., Wada H., Maeda S., et al. Increased plasma lipid-poor apolipoprotein A-I in patients with coronary artery disease. Clin Chem 2005, 51:132-137.
19. Sethi A.A., Sampson M., Warnick R., et al. High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol. Clin Chem 2010, 56:1128-1137.
20. Guey L.T., Pullinger C.R., Ishida B.Y., et al. Relation of increased prebeta-1 high-density lipoprotein levels to risk of coronary heart disease. Am J Cardiol 2011, 108:360-366.
21. O'Leary D.H., Polak J.F., Kronmal R.A., et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999, 340:14-22.
22. Hirayama S., Miida T., Miyazaki O., Aizawa Y. Pre beta1-HDL concentration is a predictor of carotid atherosclerosis in type 2 diabetic patients. Diabetes Care 2007, 30:1289-1291.
23. Selzer R.H., Hodis H.N., Kwong-Fu H., et al. Evaluation of computerized edge tracking for quantifying intima-media thickness of the common carotid artery from B-mode ultrasound images. Atherosclerosis 1994, 111:1-11.
24. van Haperen R., van Tol A., Vermeulen P., et al. Human plasma phospholipid transfer protein increases the anti-atherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol 2000, 20:1082-1088.
25. O'Connor P.M., Zysow B.R., Schoenhaus S.A., et al. Prebeta-1 HDL in plasma of normolipidemic individuals: influences of plasma lipoproteins, age, and gender. J Lipid Res 1998, 39:670-678.
26. Plomgaard P., Dullaart R.P.F., de Vries R., Groen A.K., Dahlbáck B., Nielsen L.B. Apolipoprotein M predicts pre-β-HDL formation: studies in type 2 diabetic and nondiabetic subjects. J Intern Med 2009, 266:258-267.
27. Chétiveaux M., Lalanne F., Lambert G., Zair Y., Ouguerram K., Krempf M. Kinetics of prebeta1 HDL and alpha HDL in type II diabetic patients. Eur J Clin Invest 2006, 3629-3634.
28. Rye K.A., Jensen G., Barter P.J., Ehnholm C. Triglyceride-enrichment of high density lipoproteins enhances their remodelling by phospholipid transfer protein. J Lipid Res 1998, 39:613-622.
29. van Tol A. Phospholipid transfer protein. Curr Opin Lipidol 2002, 13:135-139.
30. Jiang X.C., Bruce C., Mar J., et al. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest 1999, 103:907-914.
31. Clay M.A., Newnham H.H., Forte T.M., Barter P.I. Cholesteryl ester transfer protein and hepatic lipase activity promote shedding of apo A-I from HDL and subsequent formation of discoidal HDL. Biochim Biophys Acta 1992, 1124:52-58.
32. Ishida B.Y., Frolich J., Fielding C.J. Prebeta-migrating high density lipoprotein: quantitation in normal and hyperlipidemic plasma by solid phase radioimmunoassay following electrophoretic transfer. J Lipid Res 1987, 28:778-786.
33. Jiang X.C., Qin S., Qiao C., et al. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med 2001, 7:847-852.
34. Lie J., de Crom R., van Gent T., et al. Elevation of plasma phospholipid transfer protein in transgenic mice increases VLDL secretion. J Lipid Res 2002, 43:1875-1880.
35. Masson D., Deckert V., Gautier T., et al. Worsening of diet-induced atherosclerosis in a new model of transgenic rabbit expressing the human plasma phospholipid transfer protein. Arterioscler Thromb Vasc Biol 2011, 31:766-774.
36. de Vries R., Dallinga-Thie G.M., Smit A.J., Wolffenbuttel B.H.R., van Tol A., Dullaart R.P.F. Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus. Diabetologia 2006, 49:398-404.
37. Vergeer M., Boekholdt S.M., Sandhu M.S., et al. Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility. Circulation 2010, 122:470-477.
38. Peters S.A., den Ruijter H.M., Bots M.L. Attenuation of rate of change in carotid intima-media thickness by lipid-modifying drugs: impact on clinical outcomes. Am J Cardiovasc Drugs 2011, 11:253-263.
39. Dullaart R.P., Hoogenberg K., Dikkeschei B.D., van Tol A. Higher plasma lipid transfer protein activities and unfavorable lipoprotein changes in cigarette-smoking men. Arterioscler Thromb 1994, 14:1581-1585.
40. Godsland I.F. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001, 75:898-915.
41. Asztalos B.F., Batista M., Horvath K.V., et al. Change in alpha1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 2003, 23:847-852.
42. Asztalos B.F., Le M.F., Dallal G.E., et al. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins. Am J Cardiol 2007, 99:681-685.
43. Dallinga-Thie G.M., van Tol A., Dullaart R.P.F. Diabetes Atorvastatin lipid intervention (DALI) study group. Plasma pre beta-HDL formation is decreased by atorvastatin treatment in type 2 diabetes mellitus: Role of phospholipid transfer protein. Biochim Biophys Acta 2009, 1791:714-718.
44. de Vries R., Kerstens M.N., Sluiter W.J., Groen A.K., van Tol A., Dullaart R.P.F. Cellular cholesterol efflux to plasma from moderately hypercholesterolaemic type 1 diabetic patients is enhanced, and is unaffected by simvastatin treatment. Diabetologia 2005, 48:1105-1113.
45. Kappelle P.J., Van Tol A., Wolffenbuttel B.H.R., Dullaart R.P.F. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion. Cardiovasc Ther. 2011, 29:e89-e99.